Navigation Links
Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
Date:9/5/2007

FREISING-WEIHENSTEPHAN, Germany, September 5 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins(R) in ophthalmologic disease.

The studies reported by Pieris relate to PRS-055, an Anticalin(R) specific for VEGF. VEGF is a key factor in the regulation of neovascular permeability and is implicated in debilitating eye diseases such as age-related macular degeneration (AMD), proliferative diabetic retinopathy and retinopathy of prematurity. Intravitreal injection of PRS-055 has been shown to inhibit VEGF-induced breakdown of the blood-retinal barrier in a rabbit in vivo model. The antagonistic effect of PRS-055 has been shown to be of equivalent potency to that of the approved ophthalmology product Lucentis(R) (ranibizumab; Genentech / Novartis).

"These exciting results have demonstrated that Anticalins(R) are viable candidates as potent biotherapeutics for diseases of the eye" said Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris. "Based on the success of the PRS-055 program to date, we are now selecting technologies for depot and/or non-invasive drug delivery that will exploit the favorable size and excellent stability characteristics of Anticalins(R)."

The preclinical data on PRS-055 will be presented on September 8th, 2007, at the IV. International Symposium of the German Ophthalmological Society (DOG) in Baden-Baden, Germany.

Further information is available at http://www.pieris-ag.com

Anticalin(R) is registered trademark of Pieris AG.

For further information, please contact:

Pieris AG

Phone +49-(0)-8161-1411-400

Dr Andreas Hohlbaum,

Director of Science and Preclinical Research


'/>"/>
SOURCE Pieris AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Stem cell bank announcement validates quality of Wisconsin research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  In Atlanta, it seems everyone has a chance ... to create an expressive and dynamic community unlike any other. ... contribute to it. With their newest salon ... seeks to carry on that tradition with a unique, fresh ... salon is the newest of 13 nationwide locations, each ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD ... Reception at Purdue Research Park of West Lafayette, Indiana. , The ... outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This award ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
Breaking Biology News(10 mins):